HC Wainwright Issues Negative Estimate for Eyenovia Earnings

Eyenovia, Inc. (NASDAQ:EYEN) – Investment analysts at HC Wainwright lowered their FY2024 EPS estimates for Eyenovia in a research note issued on Monday, November 18th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.52) for the year, down from their prior forecast of ($0.51). HC Wainwright has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.10) EPS, FY2025 earnings at ($0.46) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.16) EPS and FY2028 earnings at $0.05 EPS.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period last year, the company earned ($0.18) EPS.

Other equities research analysts have also recently issued research reports about the stock. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th. LADENBURG THALM/SH SH reiterated a “neutral” rating on shares of Eyenovia in a report on Monday. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Eyenovia in a report on Friday, November 15th.

Eyenovia Price Performance

EYEN stock opened at $0.09 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.55. Eyenovia has a one year low of $0.08 and a one year high of $2.57. The stock has a market cap of $5.92 million, a PE ratio of -0.13 and a beta of 1.75. The firm has a 50 day simple moving average of $0.46 and a two-hundred day simple moving average of $0.69.

Insider Activity at Eyenovia

In other Eyenovia news, CEO Michael M. Rowe purchased 50,000 shares of Eyenovia stock in a transaction that occurred on Monday, August 26th. The shares were bought at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the completion of the transaction, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This trade represents a 151.85 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eyenovia in the 2nd quarter valued at approximately $26,000. Ground Swell Capital LLC purchased a new position in shares of Eyenovia in the 2nd quarter valued at approximately $27,000. Nations Financial Group Inc. IA ADV raised its position in shares of Eyenovia by 24.4% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the last quarter. Financial Management Network Inc. acquired a new position in Eyenovia in the 3rd quarter worth approximately $39,000. Finally, SkyView Investment Advisors LLC acquired a new position in Eyenovia in the 2nd quarter worth approximately $87,000. 25.84% of the stock is currently owned by institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.